This is a working overview of copper chelation, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-13 and is reviewed periodically as new material appears.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Copper content is measured separately by techniques such as inductively coupled plasma mass spectrometry or atomic absorption. Amino acid analysis confirms the peptide sequence after hydrolysis. Because the metal and the peptide can be quantified independently, a complete certificate of analysis normally reports both values rather than a single purity figure. This separation of measurements is important when comparing suppliers.
Solid GHK-Cu appears as a blue to blue-violet powder, and the colour is a direct consequence of copper coordination. The complex dissolves readily in water and in many polar solvents, while the free peptide behaves differently. Solubility in nonpolar media is low, which limits its use in oil-based systems. Solutions are typically prepared fresh because the dissolved form is more exposed to hydrolysis and to loss of the metal ion than the dry powder. Working concentrations are usually low, and preparation notes often specify the solvent and the order of addition.
Dry material is typically held at low temperature, often around minus twenty degrees Celsius, and protected from moisture and light. Copper complexes can release their metal ion under acidic conditions or in the presence of competing chelators. Hydrolysis of the peptide backbone is a slower but real pathway, and the histidine residue is susceptible to oxidation over long periods. Stability statements therefore depend on formulation, pH, and container, and they should be read as conditional rather than absolute.
Material described in research and cosmetic supply chains is typically a synthetic peptide supplied as a lyophilized powder. Purity is commonly reported through chromatographic separation, often at 95 percent or higher, while copper content is confirmed by separate elemental analysis. Batch variation in color and solubility can reflect residual counter-ions, moisture, or partial oxidation of the peptide. Because the complex is not a single regulatory entity, specifications differ between suppliers and are not standardized internationally.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, its terminal amino group, and a deprotonated amide nitrogen, creating a stable chelate ring. The resulting complex carries a distinctive blue to blue-violet color, which arises from copper d-d electronic transitions. In the solid state it is usually handled as a powder, while in solution the complex can dissociate and re-form depending on pH and competing ligands. The name copper tripeptide-1 is widely used in ingredient listings.
The tripeptide was first isolated from a human plasma filtrate in 1973 during studies of tissue repair factors. Later work detected the free peptide and its copper complex in saliva, urine, and wound fluid, suggesting a natural role in tissue remodeling. Plasma concentrations reported in early literature decline with age, a pattern often cited in discussions of skin aging. Whether these endogenous levels are directly functional or largely incidental remains an open question. The peptide sequence is conserved across mammalian species.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in water | Free peptide differs from the complex |
| Typical storage | approx. −20 °C, desiccated | Protect from light and moisture |
| Primary purity method | RP-HPLC with MS | Confirms peptide identity |
| Copper assay | ICP-MS or AAS | Measured separately from peptide purity |
| Main degradation routes | Metal loss, hydrolysis, oxidation | Rate depends on pH and matrix |
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, frequently paired with mass spectrometry to confirm the molecular ion. Copper content is measured separately, typically by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the chromatographic signal reports the peptide rather than the metal. Ultraviolet-visible spectroscopy provides a fast check on complex formation, since copper(II) peptide complexes absorb in the visible region. Elemental analysis and amino acid analysis are used less often but remain useful for reference standards. A gap between reported peptide purity and measured copper content is a recurring source of confusion.
Material described as GHK-Cu appears in several distinct markets, including cosmetic ingredients, laboratory reagents, and consumer products, and the quality expectations attached to each differ. A certificate of analysis generally reports peptide purity by chromatography, copper content, appearance, and residual solvents or counterions. Counterion identity matters, because the complex is usually supplied as an acetate or a similar salt, and the counterion contributes to the measured mass. Independent verification of sequence and metal stoichiometry is advisable when a material is used for quantitative work. Batch-to-batch variation is common and should be documented rather than assumed negligible.
Copper peptide solutions tend to resist degradation better than many free peptides, because the bound metal protects the N-terminus and reduces susceptibility to some peptidases. Backbone hydrolysis, oxidation of the histidine imidazole ring, and photochemical reactions remain the principal degradation routes. Aqueous solutions are generally most stable near neutral to mildly acidic pH, while strongly alkaline conditions accelerate hydrolysis. Light exposure is usually avoided, since both the peptide and the copper center can take part in photochemical processes. Stability data published by suppliers often describe short-term behavior rather than multi-year shelf life.
Published studies describe the complex in several research contexts, including collagen synthesis, antioxidant behaviour, and wound repair models. Much of this work is conducted in cultured cells or in small animal systems, and the findings are frequently cited in reviews of copper peptides. Direct clinical evidence in humans is comparatively limited, and reported outcomes vary with formulation and study design. Whether free chain or metal-bound form was used is not always stated, a point that complicates comparison between reports.
GHK-Cu is a coordination complex formed between the peptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The unbound chain, abbreviated GHK, consists of three amino acids and occurs naturally in human plasma, saliva, and urine. Binding of the metal is mediated mainly by the imidazole nitrogen of the histidine residue together with backbone amides, producing a stable chelate. Ingredient nomenclature often lists the same substance as copper tripeptide-1. Its charge and solubility behaviour differ from those of the metal-free chain.
Routine characterisation relies on reversed-phase high-performance liquid chromatography for peptide purity, paired with mass spectrometry for identity confirmation. Ultraviolet-visible spectroscopy detects the metal centre through its absorption band in the visible region, and inductively coupled plasma mass spectrometry quantifies total copper so that a metal-to-peptide ratio can be calculated. Amino acid analysis confirms the expected residue composition. Together these techniques establish concentration, identity, and stoichiometry, but none of them directly reports biological activity.
Quality specifications for research material commonly state peptide purity, copper stoichiometry, counter-ion identity, and residual water content. Frequent counter-ions include acetate and trifluoroacetate, which differ in mass and in their effect on solubility and handling. Whether batch-to-batch differences in reported responses trace to these parameters or to assay conditions remains an open question, since published comparisons rarely control for all of them at once. Independent verification therefore normally pairs a purity measurement with an elemental copper measurement on the same lot.
Laboratory studies describe GHK-Cu as a source of copper that cells can take up, with reported effects on collagen, elastin, and glycosaminoglycan synthesis in cultured fibroblasts. The peptide also appears in wound-repair research, where it is linked to the activity of matrix metalloproteinases and their inhibitors. These observations come largely from cell and animal models. How directly the complex controls any single pathway in intact human skin remains an open question, and reported effects depend on concentration, vehicle, and exposure time.
Copper takes part in redox chemistry, and the same property that makes it useful in enzymes can generate reactive oxygen species when the ion is loosely bound. GHK chelates copper through imidazole, amino, and amide nitrogen donors, which reduces the amount of free copper in solution. Whether that chelation is protective, neutral, or harmful in a given tissue is not settled. Laboratory assays report both antioxidant and pro-oxidant behavior, depending on the conditions and the readout used.
Marfan syndrome - inherited as an autosomal dominant characteristic, due to mutations in the FBN1 gene that encodes fibrillin 1. Homocystinuria - condition of methionine metabolism brought on by a cystathionine β-synthase deficit that causes a build-up of homocysteine and its metabolites in the urine and blood. Ehlers–Danlos syndrome - diverse collection of disorders distinguished by the fragility of soft connective tissues and widespread symptoms affecting the skin, ligaments, joints, blood vessels, and internal organs. Osteogenesis imperfecta - hereditary condition marked by reduced bone mass, weakened bones, increased brittleness, and short stature. Alkaptonuria - inborn error of metabolism caused by mutations in the HGO gene and homogentisate 1,2-dioxygenase deficiency. Pseudoxanthoma elasticum - rare multisystem disease marked by gradual calcification and fragmentation of elastic fibres. Mucopolysaccharidosis - a class of hereditary illnesses distinguished by the excretion of mucopolysaccharide in the urine. Fibrodysplasia ossificans progressiva - rare and debilitating hereditary disorder characterized by progressive heterotopic ossification and congenital skeletal malformations. Familial osteochondritis dissecans - separation of the subchondral bone and cartilage from the surrounding tissue. Stickler syndrome - autosomal dominant disorder distinguished by skeletal, ocular, and orofacial abnormalities.
Tendons are viscoelastic structures, which means they exhibit both elastic and viscous behaviour. When stretched, tendons exhibit typical "soft tissue" behavior. The force-extension, or stress-strain curve starts with a very low stiffness region, as the crimp structure straightens and the collagen fibres align suggesting negative Poisson's ratio in the fibres of the tendon. More recently, tests carried out in vivo (through MRI) and ex vivo (through mechanical testing of various cadaveric tendon tissue) have shown that healthy tendons are highly anisotropic and exhibit a negative Poisson's ratio (auxetic) in some planes when stretched up to 2% along their length, i.e. within their normal range of motion. After this 'toe' region, the structure becomes significantly stiffer, and has a linear stress-strain curve until it begins to fail. The mechanical properties of tendons vary widely, as they are matched to the functional requirements of the tendon. The energy storing tendons tend to be more elastic, or less stiff, so they can more easily store energy, whilst the stiffer positional tendons tend to be a little more viscoelastic, and less elastic, so they can provide finer control of movement. A typical energy storing tendon will fail at around 12–15% strain, and a stress in the region of 100–150 MPa, although some tendons are notably more extensible than this, for example the superficial digital flexor in the horse, which stretches in excess of 20% when galloping. Positional tendons can fail at strains as low as 6–8%, but can have moduli in the region of 700–1000 MPa.
== Distribution == The labeled [18F]FDG compound has a relatively short shelf life which is determined largely by the physical decay of fluorine-18 with a half-life of 109.8 minutes, or slightly less than two hours. Still, this half-life is sufficiently long to allow shipping the compound to remote PET scanning facilities, in contrast to other medical radioisotopes like carbon-11 with a half-life of ~20 minutes. Due to transport regulations for radioactive compounds, delivery is normally done by specially licensed road transport, but means of transport may also include dedicated small commercial jet services. Transport by air allows expanding the distribution area around a [18F]FDG production site to deliver the compound to PET scanning centres within a 1–3-hour flight time. Recently, on-site cyclotrons with integral shielding and portable chemistry stations for making [18F]FDG have accompanied PET scanners to remote hospitals. This technology holds some promise in the future, for replacing some of the scramble to transport [18F]FDG from site of manufacture to site of use.
== History == A phase III trial for dasiglucagon was started in July 2017. In December 2017, Zealand (Copenhagen, Denmark) announced the initiation of a phase III trial for dasiglucagon, with the intention of submitting positive outcomes to the US Food and Drug Administration (FDA) in 2019. The FDA approved dasiglucagon based on evidence from two clinical trials conducted in adults with type 1 diabetes (169 participants) and one clinical trial conducted in pediatric participants older than six years with type 1 diabetes (31 participants). The trials were conducted in the following five countries: United States, Germany, Austria, Canada, and Slovenia. The same trials were used to assess the safety and efficacy of dasiglucagon: adult Trials A and B and pediatric Trial C. In all trials, participants were randomized into one of three groups: one group received dasiglucagon, one group received placebo, and one group received glucagon for injection (a similar drug that is FDA approved for the same purpose as dasiglucagon). In all groups, participants were given insulin to decrease their blood sugar to a low level (hypoglycemia). Subjects received a single injection of either dasiglucagon, placebo, or glucagon for injection, and the ability of the treatment to increase the participants' blood sugar was evaluated.
=== Low BMD === Bone Mineral Density (BMD) tends to peak at a young age. When children are younger, they start building up their BMD through their nutrition and through exercise. BMD peaks at around 12.5 years old for girls and around 14 years old for boys. It could be caused by a deficiency in calcium or Vitamin D. Calcium is the main nutrient for bone health. It aids in the structure and density of the bone. Low BMD could be caused by the children not getting the proper exercise for adequate bone growth. Researchers suggest that children should get 20 minutes of vigorous activity 3 to 5 days a week to promote an increase in BMD. Jumping for about 5 minutes a day also stimulates an increase in BMD. Researchers did a 10-year study on the effects of vigorous intensity activity and their bone health/strength. They studied 300 boys and girls. They found that in boys going through puberty (ages 11-13), they experienced a greater bone mass growth. Their bone mass increased during this time because their bones are not ready for the mechanical stress from them growing. However, that is how the bones grow stronger and why their BMD increases. Too much stress on the bones could cause BMD to decrease. Low BMD is dangerous because it can cause disorders inside the bone as the children grow and get older. These disorders can cause the bone to ossify, become brittle, fragile, more easily prone to fractures, and weak. Some of these disorders include osteopenia, osteoporosis, and scoliosis. Scoliosis is very common in children. Low BMD plays a role in the child's scoliosis.
Sources: en.wikipedia.org
=== Colonial and Federal periods === The Bowery is the oldest thoroughfare on Manhattan Island, preceding European intervention as a Lenape footpath, which spanned roughly the entire length of the island, from north to south. When the Dutch settled Manhattan island, they named the path Bouwerie road – "bouwerie" (or later "bouwerij") being an old Dutch word for "farm" – because it connected farmlands and estates on the outskirts to the heart of the city in today's Wall Street/Battery Park area. In 1654, the Bowery's colonial residents settled in the area of Chatham Square; ten freedmen and their wives set up cabins and a cattle farm there. Petrus Stuyvesant, the last Dutch governor of New Amsterdam before the English took control, retired to his Bowery farm in 1667. After his death in 1672, he was buried in his private chapel. His mansion burned down in 1778 and his great-grandson sold the remaining chapel and graveyard, now the site of the Episcopal church of St. Mark's Church in-the-Bowery. In her Journal of 1704–05, Sarah Kemble Knight describes the Bowery as a leisure destination for residents of New York City in December:
== Purification == Single-chain variable fragments lack the constant Fc region found in complete antibody molecules, and, thus, the common binding sites (e.g., protein G) cannot be used to purify antibodies. These fragments can often be purified or immobilized using protein L, since protein L interacts with the variable region of kappa light chains. More commonly, scientists incorporate a six histidine tag on the c-terminus of the scFv molecule and purify them using immobilized metal affinity chromatography (IMAC). Some scFv can also be captured by protein A if they contain a human VH3 domain.
== History == Dexcom was founded in 1999 by Scott Glenn, John Burd, Lauren Otsuki, Ellen Preston and Bret Megargel. In 2006, Dexcom received U.S. Food and Drug Administration (FDA) approval and launched the Dexcom STS Continuous Glucose Monitoring System, which is a three-day sensor that provides up to 288 glucose measurements for every 24 hours. Dexcom received approval of the second-generation product, the Seven Continuous Glucose Monitoring System, in May 2007. This device improved on accuracy and extended use from three to seven days. In 2008, Dexcom announced two consumer development agreements with Insulet Corporation and Animas Corporation as well as a development agreement with Edwards Lifesciences for a continuous glucose monitor in the intensive care unit hospital environment. During February 2009, Dexcom received approval for the Seven Plus Continuous Glucose Monitor, its new continuous glucose monitoring system, from the FDA. This product received a CE mark in November 2009. In 2013, development work for integration with Insulet was discontinued. Dexcom entered a non-exclusive agreement with Tandem Diabetes Care, Inc. in 2015 to allow the integration of its forthcoming G5 and G6 continuous glucose monitoring systems into Tandem's insulin pumps. The G5 was approved in 2016 by the FDA for use as a standalone device, while the G6 gained approval in 2018. Dexcom's first G-series CGM, the G4 Platinum, received a CE mark and FDA approval in 2012 for adults ages 18 and over. This device improved hypoglycemic accuracy by 30%.
Specialized scalp tattoos can also mimic the appearance of a short buzzed haircut. Androgenic alopecia also occurs in women, and more often presents as diffuse thinning without hairline recession. Like its male counterpart, the condition rarely leads to total hair loss. Treatment options are similar to those for men, although topical or systemic estrogen is used more often.
Sources: en.wikipedia.org
=== Heart failure === Microarray analysis from one report shows a significant decrease in myocardial arginine:glycine amidinotransferase (AGAT) gene expression during the late-stage heart failure. This suggests that the reduced AGAT may correlate with loss of heart function. Increase of AGAT expression in the myocardium after heart failure due to increase in creatine synthesis was associated with favorable outcome.
C2 photosynthesis (also called glycine shuttle and photorespiratory CO2 pump) is a CCM that works by making use of – as opposed to avoiding – photorespiration. It performs carbon refixation by delaying the breakdown of photorespired glycine, so that the molecule is shuttled from the mesophyll into the bundle sheath. Once there, the glycine is decarboxylated in mitochondria as usual, releasing CO2 and concentrating it to triple the usual concentration. Although C2 photosynthesis is traditionally understood as an intermediate step between C3 and C4, a wide variety of plant lineages do end up in the C2 stage without further evolving, showing that it is an evolutionary steady state of its own. C2 may be easier to engineer into crops, as the phenotype requires fewer anatomical changes to produce.
=== Classification === Scleroderma is characterised by the appearance of circumscribed or diffuse, hard, smooth, ivory-colored areas that are immobile and which give the appearance of hidebound skin, a disease occurring in both localised and systemic forms:
=== Diet === There is varying evidence about the importance of saturated fat in the development of myocardial infarctions. Eating polyunsaturated fat instead of saturated fats has been shown in studies to be associated with a decreased risk of myocardial infarction, while other studies find little evidence that reducing dietary saturated fat or increasing polyunsaturated fat intake affects heart attack risk. Dietary cholesterol does not appear to have a significant effect on blood cholesterol and thus recommendations about its consumption may not be needed. Trans fats do appear to increase risk. Acute and prolonged intake of high quantities of alcoholic drinks (3–4 or more daily) increases the risk of a heart attack.
== Taxonomy == At one time, all yellow or golden chanterelles in western North America had been classified as Cantharellus cibarius. Using DNA analysis, they have since been shown to be a group of related species. In 1997, the Pacific golden chanterelle (C. formosus) and C. cibarius var. roseocanus were identified, followed by C. cascadensis in 2003, C. californicus in 2008, and C. enelensis in 2017. C. cibarius var. roseocanus occurs in the Pacific Northwest in Sitka spruce forests, as well as Eastern Canada in association with Pinus banksiana.
Sources: en.wikipedia.org
The colour comes from electronic transitions in the coordinated copper(II) ion. Ligand field effects absorb part of the visible spectrum. A colourless or greenish sample may indicate degraded material.
Copper can be displaced by other metal ions, by strong chelating agents, or by low pH. Samples exposed to these conditions may contain a mixture of free peptide and complex. Analytical testing is the only reliable way to confirm the bound fraction.
Solution storage generally shortens shelf life compared with the dry powder. Hydrolysis and oxidation proceed faster in aqueous media. Where solutions are used, cold storage and short holding times reduce measurable change.
It is a complex of the tripeptide glycyl-L-histidyl-L-lysine with a copper(II) ion. The peptide coordinates the metal through its histidine, amino terminus, and an amide nitrogen. It is often listed simply as copper tripeptide-1.